Stocks and Investing Stocks and Investing
Fri, March 10, 2023
Thu, March 9, 2023

Michael Higgins Reiterated (VRDN) at Strong Buy and Held Target at $40 on, Mar 9th, 2023


Published on 2024-10-28 02:12:05 - WOPRAI, Michael Higgins
  Print publication without navigation


Michael Higgins of Ladenburg Thalmann, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $40 on, Mar 9th, 2023.

Michael has made no other calls on VRDN in the last 4 months.



There are 4 other peers that have a rating on VRDN. Out of the 4 peers that are also analyzing VRDN, 0 agree with Michael's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Michael


  • Thomas Smith of "SVB Leerink" Maintained at Buy with Increased Target to $45 on, Monday, January 9th, 2023
  • Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $45 on, Monday, December 19th, 2022
  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $51 on, Friday, December 16th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022

Contributing Sources